1 / 7

The Clinical Application of CD19-CART Cells

The study of CD19 CART cells is currently a hot spot for B-cell lymphomas. In 2010, Kochenderfer et al. first reported the role of CD19-CART cells in the treatment of relapsed and refractory follicular lymphoma. In 2012, Kochenderfer et al. reported that 8 patients with relapsed and refractory B-cell lymphoma received CART cell therapy, including 4 CLL, 3 follicular neoplasms, and 1 splenic marginal B-cell lymphoma.<br>

bellasmith123
Download Presentation

The Clinical Application of CD19-CART Cells

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Clinical Application of CD19-CART Cells

  2. The study of CD19 CART cells is currently a hot spot for B-cell lymphomas. In 2010, Kochenderfer et al. first reported the role of CD19-CART cells in the treatment of relapsed and refractory follicular lymphoma. In 2012, Kochenderfer et al. reported that 8 patients with relapsed and refractory B-cell lymphoma received CART cell therapy, including 4 CLL, 3 follicular neoplasms, and 1 splenic marginal B-cell lymphoma.

  3. CD19-CART cells can recognize specific CD19 targets of B-cell lymphocytic leukemia. By releasing cytokines such as perforin and granzymes, CD19-CART cells attack the B lymphocytes expressing CD19 antigen, thereby prompting the body to eliminate malignant lymphocytes. The US Sloan-Kettering Cancer Center applied autologous 19-28z CART in the treatment of refractory and relapsed B-ALL. Fourteen of the 16 patients had CR and were even effective in relapsed Ph+ ALL after transplantation. Treatment with CART also creates conditions for allogeneic hematopoietic stem cell transplantation. The University of Pennsylvania also reported the use of 19-CD137zCART for the treatment of B-cell tumors. Thirty patients with refractory and relapsed B-ALL and 27 patients achieved CR. The 6-month disease-free survival rate was 67%, and the overall survival rate was 78%.

  4. Brenyjens et al. used second CAR T generation cells, CD19-specific CART cells transfected with CD28/CD3-ζ, to treat 5 patients with relapsed B-ALL. The number and function of CART cells were detected by PCR sequencing. The results showed that CART cells could rapidly produce anti-tumor effects in vivo, and the detection of minimal residual disease turned to negative soon and reached CR. Grupp et al. reported CR in 2 patients with refractory and relapsed B-ALL treated with 2nd generation CART cells. One of them was relapsed after umbilical cord blood allogeneic hematopoietic stem cell transplantation and had dual specificity for CD3 and CD19.

  5. About Creative Biolabs As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, we are the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline. Additionally, we also offer an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, we have built up a unique unparalleled CAR construction and production platform for all four CAR generations.

  6. Contact us 45-1 Ramsey Road, Shirley, NY 11967, USA Email: marketing@creative-biolabs.com

  7. Thank you

More Related